In a bid to bolster protection against the ongoing COVID-19 surge, the Australian federal government has unveiled the imminent availability of updated vaccines from December 11, just in time for Christmas. These new monovalent vaccines, differing from previous bivalent boosters, specifically target the XBB.1.5 subvariant, closely related to the circulating Pirola and Eris strains.
Australia has been grappling with a fresh wave of COVID-19, marked by rising case numbers and indicators of severe disease across the country. The World Health Organization (WHO) is closely monitoring the Pirola variant, while Eris has been classified as a variant of interest due to its prevalence. The shift towards monovalent vaccines aligns with WHO recommendations to move away from the original strain, preventing immunity buildup to an outdated virus. The Australian Technical Advisory Group on Immunisation (ATAGI) emphasizes the benefits of the new vaccines, stating they provide modestly enhanced protection from severe disease compared to older formulations.
The two major pharmaceutical players, Pfizer and Moderna, have crafted these mRNA vaccines, available for children aged five and above as well as adults. The government’s decision to roll out the new vaccines reflects a commitment to offering the latest and most effective options, while existing bivalent vaccines will continue to be available alongside the new formulations. Despite the urgency posed by the current COVID-19 surge, ATAGI maintains its eligibility recommendations, advising against the updated vaccine for those up to date with 2023 boosters or who received their primary dose within the last six months. The rollout of these new vaccines is set for December 11, with healthcare providers able to commence administration upon receiving their orders.
While experts acknowledge pandemic fatigue and frustration, they stress the importance of continued vaccination efforts to curb the spread. With an estimated 3 to 5 million Australians projected to contract COVID-19 in the next few months, a deliberate global effort to reduce transmission is deemed crucial for a sustainable resolution to the ongoing health crisis.
